Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study.
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and benzodiazepine anxiolytics are used in the US to treat generalized anxiety disorder (GAD). While benzodiazepines typically provide rapid symptomatic relief, long-term use is not recommended due to risks of dependency, sedation, falls, and accidents. METHODS: Using a US health insurance database, we identified all persons with GAD (ICD-9-CM diagnosis code 300.02) who began a long-term course of treatment (≥ 90 days) with a benzodiazepine anxiolytic between 1/1/2003 and 12/31/2007, We compared healthcare utilization and costs over the six-month periods preceding and following the date of treatment initiation ("pretreatment" and "post-treatment", respectively), and focused attention on accident-related encounters (e.g., for treatment of fractures) and care received for other reasons possibly related benzodiazepine use (e.g., sedation, dizziness). RESULTS: A total of 866 patients met all study entry criteria; 25% of patients began treatment on an add-on basis (i.e., adjunctive to escitalopram, paroxetine, sertraline, or venlafaxine), while 75% of patients did not receive concomitant therapy. Mean total healthcare costs increased by $2334 between the pretreatment and post-treatment periods (from $4637 [SD=$9840] to $6971 [$17,002]; p<0.01); costs of accident-related encounters and other care that was possibly related to use of benzodiazepines increased by an average of $1099 ($1757 [$7656] vs $2856 [$14,836]; p=0.03). CONCLUSIONS: Healthcare costs increase in patients with GAD beginning long-term (≥ 90 days) treatment with a benzodiazepine anxiolytic; a substantial proportion of this increase is attributable to care associated with accidents and other known sequelae of long-term benzodiazepine use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The monthly probability of hospitalization in state of severe symptoms was approximated from the findings of a retrospective cohort study of health care utilization among patients with generalized anxiety disorders over a 6-month follow-up period [23].”
From Cost-effectiveness of internet-supported cognitive behavioral therapy for university students with anxiety symptoms: A Markov-model analysis (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“Lifetime prevalence of GAD has been estimated to be about 4-6% [3]; one-year prevalence has been reported to be about 2% [4,5].”
BackgroundDiagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Explicit Criteria for Determining Inappropriate Medication Use in Nursing Home Residents
Beers, M. H. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400090107019 · Cited by 1,201 · cited 1×
“These concerns are heightened in older patients, as risk of adverse events generally increases with age [12-14, 21-23].”
BackgroundExplicit Criteria for Determining Potentially Inappropriate Medication Use by the Elderly: An Update
Beers, M. H. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440350031003 · Cited by 1,059 · cited 2×
“Total healthcare costs increased by $2980 among patients aged ≥50 years ($6211 [$13,308] vs 9191 [22,540]; p=0.”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854 · cited 2×
“Current treatment guidelines for GAD recommend first-line treatment with antidepressants—specifically, escitalopram, paroxetine, or sertraline (all selective serotonin re-uptake inhibitors [SSRI]), or venlafaxine (a serotonin-norepinephrine reuptake inhibitor [SNRI])—or pregabalin on the basis of their efficacy, safet…”
BackgroundGeneralized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733 · cited 1×
“GAD is the most common anxiety disorder among patients presenting to primary care physicians [6,7], and it is overrepresented in primary care settings, with point prevalence rates at least 2–3 times higher than those reported in the community [7,8].”
BackgroundOrmel, E. A. (1995) · PsycEXTRA Dataset · doi:10.1037/e536912011-072 · Cited by 706
Ormel, J. (1994) · JAMA · doi:10.1001/jama.1994.03520220035028 · Cited by 642 · cited 1×
“GAD is the most common anxiety disorder among patients presenting to primary care physicians [6,7], and it is overrepresented in primary care settings, with point prevalence rates at least 2–3 times higher than those reported in the community [7,8].”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617 · cited 1×
“, escitalopram, paroxetine, sertraline, venlafaxine, imipramine, buspirone, hydroxyzine, trifluoperazine) [9,40] or any other agent from any corresponding class of medication (e.”
Background
Cited by
‘Big data’ in mental health research: current status and emerging possibilities
Stewart, R., & Davis, K. (2016) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-016-1266-8 · Cited by 79
“[132]”
Hovenkamp-Hermelink, J. H., Riese, H., van der Veen, D. C., Batelaan, N. M., Penninx, B. W., & Schoevers, R. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.10.035 · Cited by 49
Fegadolli, C., Varela, N. M. D., & Carlini, E. A. (2019) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00097718 · Cited by 57
Markett, S. A., Montag, C., Melchers, M., Weber, B., & Reuter, M. (2016) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-016-0451-2 · Cited by 28
You, J. H. S., Luk, S. W. C., Chow, D. Y. W., Jiang, X., Mak, A. D. P., & Mak, W. W. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268061 · Cited by 18
“37% Beta [23] Age-specific (18–22 years) all-cause mortality 0.”
BackgroundInfluential
Metadata
- Authors
- Berger, A., Edelsberg, J., Treglia, M., Alvir, J. M. J., & Oster, G.
- Affiliations
- Policy Analysis (United States) (US)
- Pfizer (United States) (US)
- Corresponding author
- Berger, Ariel
- Venue
- BMC Psychiatry
- Published
- 2012-10-23
- Volume
- 12
- Issue
- 1
- Pages
- 177-177
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC3504522
- OpenAlex
- W2009527779
- Cited by
- 17
- References
- 52
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 5 · 2015: 1 · 2013: 1
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- generalized anxiety disorder, benzodiazepines, health care utilization, health care costs, sedation, dizziness, selective serotonin reuptake inhibitors, adjunctive therapy
- MeSH terms
- Adult, Aged, Anxiety Disorders, Benzodiazepines, Delivery of Health Care, Female, Humans, Insurance, Health, Long-Term Care, Male, Middle Aged, Retrospective Studies, Anti-Anxiety Agents, Treatment Outcome, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study. https://app.cochat.ai/papers/10.1186/1471-244x-12-177
- The paper
- Berger, A., Edelsberg, J., Treglia, M., Alvir, J. M. J., & Oster, G. (2012). Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study. BMC Psychiatry. https://doi.org/10.1186/1471-244x-12-177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.